Myriad Announces Seven New Payer Coverage Decisions for Prolaris

Myriad Genetics (NASDAQ:MYGN), a worldwide leader in personalized medicine, today announced seven new commercial coverage decisions for Prolaris^®, the company’s market leading prognostic test for patients with prostate cancer.  The payers include a top-25 commercial insurer in the United States and in aggregate the payers represent six million new covered lives for Prolaris.

As quoted in the press release:

These decisions follow the recently updated National Comprehensive Cancer Network (NCCN) guidelines that support Prolaris as standard of care in making treatment decisions for patients with low and favorable-intermediate risk prostate cancer.

“We are extremely pleased to see accelerating commercial insurer coverage for Prolaris based upon the strong supporting clinical evidence which was underscored by recent NCCN guidelines,” said Nicole Lambert, general manager, Urology.  “These decisions will ensure broader patient access to Prolaris allowing for more informed clinical decision making and lower overall healthcare costs to the system.”

In aggregate, Prolaris now has insurance coverage for approximately 50 percent of Prostate cancer patients in the United States. Over 60,000 men have received the Prolaris test to help guide their treatment for prostate cancer.

Click here to read the full press release.